Alopecia Areata Case Puts Psychosocial Burden Front and Center
A Dermatology Times case discussion zeroes in on psychosocial burden and realistic treatment goals for a patient with alopecia areata.
Topic
Alopecia Areata
Topic
Alopecia Areata
Alopecia Areata Reframed as a Medical Disease, Not a Cosmetic Concern
Dermatology Times reframes alopecia areata as a medical, autoimmune disease, outlining how clinicians should define severity and…
Expert Panel Releases Oral Minoxidil Consensus for Preteens
An expert panel has released a consensus statement aimed at clarifying oral minoxidil use in preteens, addressing an off-label pr…
Upadacitinib Linked to Rapid Response in Acute Diffuse Alopecia Areata
A JAAD brief report from Huashan Hospital describes rapid and substantial improvement with upadacitinib in acute diffuse alopecia…
REZOLVE-AA Trial Reports Durable Hair Regrowth With Rezpegaldesleukin
REZOLVE-AA topline data show rezpegaldesleukin produces durable hair regrowth in alopecia areata, per Dermatology Times — a susta…
JAAD Study Defines New Phenotype: Altered Hair Texture After Alopecia Areata Regrowth
A JAAD study published October 8, 2026 defines post-regrowth hair texture change in alopecia areata as a distinct clinical and ul…
Nektar Reports Durable Hair Regrowth With REZPEG, Phase III Alopecia Trial Next
Nektar says REZPEG produced durable hair regrowth in alopecia patients, and the data set up a Phase III trial of the candidate in…
Rezpegaldesleukin Long-Term Data Unveiled at EADV 2026
New rezpegaldesleukin data presented at EADV Congress 2026 support long-term durability and disease improvement in both alopecia…
REZOLVE-AA Trial Reports Durable Hair Regrowth With Rezpegaldesleukin
Rezpegaldesleukin delivered durable hair regrowth in the REZOLVE-AA alopecia areata trial, strengthening the case for selective I…
Rezpegaldesleukin Long-Term Data to Feature at EADV 2026
New rezpegaldesleukin data supporting long-term durability and disease improvement in alopecia areata and atopic dermatitis will…